HomecollectionsWebinarsQuantification of Mutant and Total Huntington Protein Levels

Quantification of Mutant and Total Huntington Protein Levels Webinar


Assay Development for Quantification of Low-abundance Proteins Using Single Molecule Counting

What Does it Cover?

Huntington Disease is caused by the expression of a mutated form of the Huntingtin protein (mHTT) containing a polyglutamine (polyQ) repeat, with the length of the repeat correlating to increased severity of the disease. Since concentrations of total and mHTT in premanifest and controls groups are extremely low, it is imperative that detection assays are capable of reaching femtomolar levels of sensitivity. By employing SMC™ technology, we can provide the HD community with tools to enable a better understanding of the disease and to assist in the development of new therapeutics.

During this webinar we will review data from the development and validation of the high sensitivity SMC™ immunoassays for the quantification of mHTT and total HTT.

What Will You Learn?

  • General background on Single Molecule Counting (SMC™) technology
  • How our SMC™ platform can be used to detect very low levels of Huntingtin protein
  • How to reach femtomolar levels of sensitivity by detecting both mHTT and total HTT
  • Development and validation of high sensitivity SMC™ immunoassays


Sarah Hamren

Head of Custom Assays & Sample Testing

Sarah J. Hamren has led the 10 member SMC™ Custom Assay and Sample Testing group since 2015; 7 team members report directly to Sarah. She has over 30 years of experience in biopharma research and development. Previously the Director of Assay Development of the Life Science Division for Singulex, Sarah has been responsible for the successful transfer of the Singulex Life Science business unit, marketing, sales, manufacturing, quality control, accounts receivable, international reagent shipment, and customer support since its 2015 acquisition. Drawing on her past experience working with Chiron Corporation (now part of Novartis), Bayer Corporation’s Biotechnology division, Tethys Bioscience, and Singulex, maintaining the high-quality services clients expect from us has been her constant goal. She is co-author on 15 peer-reviewed publications and holds 2 U.S. patents. Sarah’s 12 years of experience effectively partnering with a broad array of clients have culminated in 100s of successful biomarker assay development projects. She has proven success overcoming the limitations of challenging sample types and very small sample volumes while at the same time adhering to project deadlines, budgets, and the highest standards of quality control.